We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
External link for Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285, US
Positive results for patients with biomarker-driven early-stage non-small cell lung cancer to be shared at the ASCO Annual meeting. See more from Lilly Oncology.
As part of the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, Lilly will share results from a Phase 3 lung cancer study of an adjuvant therapy for patients with biomarker-driven early stage non-small cell lung cancer (NSCLC). Learn more about these data: https://e.lilly/3RGnrSz #LungCancer #ASCO26
Announcing a major milestone in obesity care: all three of the nation's largest pharmacy benefit managers will cover Lilly's full obesity medicine portfolio. Treatment may be within reach now more than ever before, giving patients and doctors more flexibility to choose what best meets a person’s needs. See if you have coverage: https://lnkd.in/eDn4y49Z
Big week ahead in diabetes and obesity science. Lilly researchers will be heading to #ADA2026 with new data across our suite of medicines - building toward a new era of choice in cardiometabolic care. Stay tuned — there's a lot to share. Read more: https://lnkd.in/eDj_eeS3
Advancements in investigational treatment options are opening new doors for cardiovascular care, with the potential to transform from chronic management to one-time treatment delivering lasting impact. At Lilly, we’re harnessing this potential to reshape the future of cardiovascular care and help people living with the society's hardest hitting disease. Learn more: https://lnkd.in/gdv-GcFM #WeAreLilly
For people at high risk for heart attack or stroke, maintaining low LDL cholesterol over time is a key part of reducing risk and current care often relies on lifelong treatment. Insights from human genetics are informing research into new pathways, including a potential one-time treatment. Today, early-phase findings presented at #EASCongress2026 and published in NEJM Group add to the science shaping the future of cardiovascular care. Learn more: https://lnkd.in/eJ5ysYTm
Brain health is women's health. For 150 years, we've made medicines so people can get more of everything else. That work continues — including in brain health, where the need for better answers is urgent and personal for millions of women and their families. Grateful to Hearst for convening this year's Women's Health Lab, and to everyone working to move this conversation forward. #WeAreLilly #Lilly150 Getty Images for Hearst Magazines
Medicines alone aren't enough. Helping people get access to the care they need matters just as much. #WeAreLilly
What does it take to turn global commitments on non communicable diseases into prevention and care that people can actually access? At the World Health Assembly, WHO Foundation and Eli Lilly and Company convened key stakeholders to explore integrated care for NCDs, including the rising burden of obesity and dementia. More than 1 billion people globally are living with obesity, increasing pressure on health systems and contributing to a growing number of chronic health complications. Dementia presents a different challenge. The number of people living with dementia worldwide is projected to nearly triple to more than 150 million by 2050, with low and middle income countries expected to be most affected. The challenge now is ensuring health systems are equipped to turn progress into long term care people can consistently access over time. Learn more: https://lnkd.in/eD68RFR8
Why is it so hard to maintain long-term weight loss? Without a plan for maintenance, your body may work to push your weight back up. Learn more: https://lnkd.in/e_Yjver4 #WeAreLilly
Johnny reads his machines by feel — the vibrations, the rhythm, the moment something's stuck. His team didn't just gain a great operator. They gained a teammate who shows them a different way of seeing the work. #WeAreLilly
Today, we announced new data from the latest Phase 3 study of retatrutide, an investigational triple hormone receptor agonist being studied for adults living with obesity or overweight with at least one weight-related comorbidity. Explore the results here: https://lnkd.in/ePYtPH_M